TNXP NASDAQ
Tonix Pharmaceuticals Holding Corp.
1W: -9.6%
1M: -33.4%
3M: -29.9%
YTD: -46.2%
1Y: -62.8%
3Y: -99.6%
5Y: -100.0%
$8.91
-0.32 (-3.47%)
Weekly Expected Move ±4.8%
$8
$8
$9
$9
$10
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
30 relationships30
As Filer
counterparties named
0
As Counterparty
mentioned by others
6
Rel. Types
2021-04-19
Earliest Filing
2025-06-11
Latest Filing
partner: 18
target: 4
acquirer: 3
customer: 2
investor: 2
supplier: 1
Counterparties (Filed by TNXP)
30 relationshipsCompanies named in TNXP's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| A.G.P./Alliance Global Partners | — | partner | Sales Agent for the issuance and sale of Common Stock | 2025-06-11 | View |
| A.G.P./Alliance Global Partners | — | partner | Sales Agent for the issuance and sale of Common Stock | 2024-07-30 | View |
| Defense Threat Reduction Agency | — | customer | U.S. Government agency funding development of TNX-4200 antiviral program | 2024-07-01 | View |
| Advanced Technology International | — | partner | Entity acting on behalf of the Medical CBRN Defense Consortium to facilitate the agreement | 2024-07-01 | View |
| Tonix Pharmaceuticals Holding Corp. | TNXP | acquirer | Company issuing securities in the registered direct offering | 2024-03-29 | View |
| A.G.P./Alliance Global Partners | — | partner | Placement agent for the registered direct offering of securities | 2024-03-29 | View |
| A.G.P./Alliance Global Partners | — | acquirer | Placement agent for the registered direct offering | 2023-12-21 | View |
| Tonix Pharmaceuticals Holding Corp. | TNXP | target | Company entering into a placement agency agreement for a registered direct offering | 2023-12-21 | View |
| A.G.P./Alliance Global Partners | — | partner | Lead placement agent for the securities offering | 2023-09-29 | View |
| Brookline Capital Markets | — | partner | Co-placement agent for the securities offering | 2023-09-29 | View |
| Tonix Pharmaceuticals Holding Corp. | TNXP | target | Company entering placement agency agreement for securities offering | 2023-09-29 | View |
| Tonix Pharmaceuticals Holding Corp. | TNXP | partner | Company issuing securities in the placement | 2023-07-28 | View |
| A.G.P./Alliance Global Partners | — | partner | Lead placement agent for the offering | 2023-07-28 | View |
| Brookline Capital Markets | — | partner | Co-placement agent for the offering | 2023-07-28 | View |
| Lowenstein Sandler LLP | — | partner | Company's counsel providing opinion | 2023-07-28 | View |
| EisnerAmper LLP | — | partner | Providing comfort letter | 2023-07-28 | View |
| Haley Giuliano LLP | — | partner | Company's intellectual property counsel | 2023-07-28 | View |
| Brownstein Hyatt Farber Schreck LLP | — | partner | Company's local Nevada counsel | 2023-07-28 | View |
| Tonix Medicines, Inc. | — | customer | Purchaser acquiring assets and receiving transition services | 2023-07-03 | View |
| Tonix Pharmaceuticals Holding Corp | TNXP | partner | Parent company of Tonix Medicines, Inc. | 2023-07-03 | View |
| Upsher-Smith Laboratories, LLC | — | supplier | Seller providing transition services | 2023-07-03 | View |
| Upsher-Smith Laboratories, LLC | — | target | Seller of purchased assets in the asset purchase agreement | 2023-06-26 | View |
| Tonix Medicines, Inc. | — | partner | Purchaser of assets and parent company guarantor | 2023-06-26 | View |
| Tonix Pharmaceuticals Holding Corp. | TNXP | partner | Parent company providing guaranty for the transaction | 2023-06-26 | View |
| Lincoln Park Capital Fund, LLC | — | investor | Investor purchasing up to $80 million of common stock | 2021-12-03 | View |
| Tonix Pharmaceuticals Holding Corp. | TNXP | target | Company selling common stock to investor | 2021-12-03 | View |
| Southern Research | SOJF | partner | Seller of R&D facility and research collaboration partner for vaccine development | 2021-07-27 | View |
| TONIX PHARMACEUTICALS HOLDING CORP. | TNXP | acquirer | Company selling common stock to investor | 2021-05-14 | View |
| LINCOLN PARK CAPITAL FUND, LLC | — | investor | Investor purchasing up to $80 million of common stock | 2021-05-14 | View |
| OyaGen, Inc. | — | partner | Exclusive worldwide licensing agreement for TNX-3500 to develop antiviral SARS-CoV-2 inhibitor | 2021-04-19 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-02 | Other Events | View | |
| 2026-09-22 | Other Events; Exhibits | View | |
| 2026-09-08 | Other Events; Exhibits | View | |
| 2026-08-18 | Officer/Director Change; Other Events | View | |
| 2026-08-10 | Earnings Release; Exhibits | View | |
| 2026-08-03 | Regulation FD; Other Events; Exhibits | View | |
| 2026-07-21 | Officer/Director Change | View | |
| 2026-07-13 | Regulation FD; Other Events; Exhibits | View | |
| 2026-06-29 | Regulation FD; Other Events; Exhibits | View | |
| 2026-06-08 | Regulation FD; Other Events; Exhibits | View | |
| 2026-05-27 | Regulation FD; Other Events; Exhibits | View | |
| 2026-05-15 | Regulation FD; Other Events; Exhibits | View | |
| 2026-05-07 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-05-06 | Regulation FD; Other Events; Exhibits | View | |
| 2026-05-01 | Earnings Release; Other Events | View | |
| 2026-04-29 | Regulation FD; Other Events; Exhibits | View | |
| 2026-04-23 | Regulation FD; Other Events; Exhibits | View | |
| 2026-03-31 | Regulation FD; Other Events; Exhibits | View | |
| 2026-03-26 | Regulation FD; Other Events; Exhibits | View | |
| 2026-03-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR